首页> 外文OA文献 >A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

【2h】

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

机译：临床药物相互作用研究，评估质子泵抑制剂，P-糖蛋白/细胞色素450酶（CYP）3A4组合抑制剂和CYP2C9抑制剂对vismodegib药代动力学的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Vikram Malhi; Dawn Colburn; Sarah J. Williams; Cornelis E. C. A. Hop; Mark J. Dresser; Priya Chandra; Richard A. Graham;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib [J] . Malhi Vikram, Colburn Dawn, Williams Sarah J., Cancer chemotherapy and pharmacology. . 2016,第1期

机译：临床药物相互作用研究，评估质子泵抑制剂，P-糖蛋白/细胞色素450酶（CYP）3A4组合抑制剂和CYP2C9抑制剂对vismodegib药代动力学的影响
2. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects [J] . Clinical drug investigation . 2020,第6期

机译：临床药物 - 药物相互作用研究，以评估p-糖蛋白抑制剂，CYP3A抑制剂和CYP3A诱导剂对健康受试者的纳利胺的药代动力学的影响
3. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. [J] . Yeh RF, Gaver VE, Patterson KB, JAIDS: Journal of acquired immune deficiency syndromes . 2006,第1期

机译：洛匹那韦/利托那韦诱导健康志愿者的细胞色素P450酶CYP2C9，CYP2C19和CYP1A2的肝活性，但抑制CYP3A的肝和肠活性。
4. The Prevalence of Potential Clinically Significant Drug Interactions with Angiotensin-Converting Enzyme Inhibitors in Slovenia [C] . Marjetka P., Brane L, Polonca F. European Congress of Pharmacology . 2012

机译：斯洛文尼亚血管紧张素转化酶抑制剂潜在临床显着的药物相互作用的患病率
5. In vitro interactions of natural health products with P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4): Relevance to HIV therapies (Immune deficiency). [D] . Budzinski, Jason William. 2003

机译：天然保健品与P-糖蛋白（P-gp）和细胞色素P450 3A4（CYP3A4）的体外相互作用：与HIV治疗的相关性（免疫缺陷）。
6. A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib [O] . Vikram Malhi, Dawn Colburn, Sarah J. Williams, -1

机译：临床药物相互作用研究评估质子泵抑制剂P-糖蛋白/细胞色素450酶（CYP）3A4组合抑制剂和CYP2C9抑制剂对vismodegib药代动力学的影响
7. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects [O] . Kazuya Fukumura, Nao Kawaguchi, Toru Ishibashi, 2020

机译：临床药物 - 药物相互作用研究，以评估p-糖蛋白抑制剂，CYP3A抑制剂和CYP3A诱导剂对健康受试者的纳利胺的药代动力学的影响

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

著录项

相似文献

相关主题

期刊订阅